Explore /
Poster
/ BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.

BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.

Authors

Manish R. Patel

Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL

Manish R. Patel , Dejan Juric , Brian S. Henick , Linda R. Duska , Rentian Wu , Jian Guo , Hui Zhang , Kate Newberry , Mikael Rinne , Timothy A. Yap

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT05252416

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3095)

DOI

10.1200/JCO.2023.41.16_suppl.3095

Abstract #

3095

Poster Bd #

293

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Annual Meeting

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.

First Author: Timothy A. Yap

Poster

2022 ASCO Annual Meeting

CDK4/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression.

CDK4/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression.

First Author: Laura Sabina Lapuchesky

Poster

2024 ASCO Annual Meeting

TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC)<sup> </sup>estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.

TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC)estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.

First Author: Melinda L. Telli

Poster

2023 ASCO Annual Meeting

Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.

Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.

First Author: Ryan C. Lynch